- Home /
- Clinic Types /
- NAD+ & Peptide Therapy
Medical Director for NAD+ and Peptide Therapy Clinics: What You Need and How to Hire
Most NAD+ clinics need a medical director. Giving NAD+ by IV makes it an infusion service, so almost every state requires a physician to sign off on standing orders and screening rules. Add peptides to the menu, and you take on a second set of FDA rules, ones that keep shifting. One medical director needs to cover both, or your clinic is exposed.
Key Takeaways
- NAD+ and peptide therapy clinics face dual compliance requirements: physician oversight for IV infusion services, and FDA and state compounding rules for compounded peptide products. (Jump to Section →)
- NAD+ delivered intravenously is an IV infusion. It requires physician standing orders, patient screening protocols, and adverse event procedures in most states. (Jump to Section →)
- Compounded peptides are under active FDA review in 2026. A medical director who understands both IV protocols and compounding rules is not optional for this clinic type. (Jump to Section →)
- Medical Director Co. places NAD+ and peptide clinic medical directors within 24 hours, with physicians pre-vetted for both IV infusion and compounding clinic experience. (Jump to Section →)
The Dual Compliance Requirement for NAD+ and Peptide Therapy Clinics
NAD+ and peptide clinics answer to two separate compliance systems. Most single-service clinics only ever have to staff for one of these systems. A clinic offering both NAD+ and peptides has to satisfy both at the same time.
- IV infusion oversight: When NAD+ is delivered intravenously, most states require a physician to write standing orders, approve screening criteria, and set adverse event protocols before treatment starts.
- Compounding compliance: Peptides like BPC-157, TB-500, and CJC-1295 are not FDA-approved drugs, so a licensed compounding pharmacy can only dispense them under a valid physician prescription.
The FDA’s list of which peptides qualify for compounding changed more than once in 2026, which means a protocol that was compliant in January may not be compliant by summer. A clinic offering both services needs one physician who tracks both rulebooks in real time, not two consultants who each cover half the picture.
NAD+ IV Infusion Compliance Requirements
NAD+ delivered by IV is regulated as infusion therapy. That means every state requires a physician to approve standing orders, screening criteria, and adverse event protocols before a clinic administers it. State enforcement of this requirement is intensifying in 2026.
- Texas: House Bill 3749, known as Jenifer's Law, restricts who may administer elective IV therapy and requires written delegation between the supervising physician and any nurse practitioner or physician assistant on staff.
- California: State regulators conduct random audits of IV clinics to confirm that a contracted medical director is actively providing oversight, not just lending a license.
- Florida: Nurse practitioners must operate under a written collaborative agreement with a physician, and an NP cannot own or run a med spa without one.
These state actions point to the same trend: regulators are checking whether a medical director is actually engaged, not just listed on paperwork. Your medical director needs to stay available during infusion hours, review every adverse event, and update standing orders each time a new NAD+ protocol enters use.
The 2026 FDA Peptide Review: What Clinics Need to Know
The FDA still hasn’t settled which peptides clinics can legally compound in 2026. Some of the most requested peptides right now sit in a gray zone: not officially approved, not officially banned. That can change again any month.
- Section 503A baseline: A compounding pharmacy can only prepare a peptide if it appears on the FDA's approved 503A Bulks List, matches an existing pharmacopeia monograph, or is a component of an already-approved drug.
- BPC-157, TB-500, and CJC-1295: These peptides were removed from the FDA's restricted category earlier in 2026 after manufacturers withdrew related safety nominations, but that removal did not add them to the approved list.
- The July 2026 Pharmacy Compounding Advisory Committee vote: The panel recommended allowing compounding of BPC-157, KPV, TB-500, and MOTS-c, but the FDA has not adopted that recommendation as a final rule.
A peptide’s legal status can change between one committee meeting and the next, which means a protocol built around today’s approved list can fall out of compliance within months. Clinics need a medical director who checks a peptide’s current classification before every new patient start, not one who wrote the protocol once and filed it away.
What Your Medical Director Must Know About Compounded Peptide Compliance
Your medical director needs to verify that any compounding pharmacy the clinic uses is properly licensed and currently compliant with state board of pharmacy rules. They also need to confirm which specific peptides are lawful to dispense right now, and document that verification in writing. A medical director who cannot answer which peptides are currently compoundable in your state, today, is not qualified to sign off on your protocols.
What the Medical Director Does at a NAD+ and Peptide Therapy Clinic
Your medical director basically has two jobs here. Part of it is the same oversight any IV clinic needs. The rest only exists because peptides are compounded drugs, and compounded drugs come with their own paperwork.
Standing Orders
The medical director writes and approves standing orders for every NAD+ IV formulation the clinic offers.
Peptide Protocols
The medical director writes and approves treatment protocols for every peptide the clinic offers.
Patient Screening
The medical director sets screening and eligibility criteria for both IV and peptide services.
Adverse Event Response
The medical director builds separate response protocols for IV infusion incidents and for peptide-related incidents.
Pharmacy Verification
The medical director confirms that any compounding pharmacy partner holds current, valid licensure.
Peptide Legality Checks
The medical director confirms which peptides are lawful to dispense under current FDA guidance before adding them to the menu.
Chart Review
The medical director reviews patient charts at required intervals and signs off on new formulation additions.
Documentation
The medical director keeps records that prove oversight is active, not just a name attached to a license.
Skip one of these, and you’ve got a clinic running with paperwork gap and no real physician oversight at all. A name on a contract doesn’t protect you if nobody’s actually doing the work.
How Medical Director Co. Serves NAD+ and Peptide Therapy Clinics
Medical Director Co. places physicians who already have direct experience with both IV infusion oversight and compounded peptide protocols. Placement takes 24 hours, and pricing is $799 per month with no setup fees and no long-term contract. Every agreement is reviewed by our in-house healthcare attorney, Bolton Harris, J.D., and addresses both compliance layers directly rather than treating IV infusion and compounding as separate afterthoughts.
Get Your NAD+ and Peptide Clinic Medical Director in 24 Hours
Operating an NAD+ and peptide clinic without a medical director who understands both compliance layers is a legal exposure that grows with every patient you treat. The same states cited earlier, Texas, California, and Florida, are actively enforcing this exact requirement, and closing the gap now costs far less than fighting a citation after the fact. Medical Director Co. places a pre-vetted physician for your clinic type in 24 hours, with attorney-reviewed agreements and no setup fees.
Stop Treating Patients Without Coverage
Get a vetted NAD+ and peptide physician in 24 hours, zero setup fees.
FAQ
NAD+ delivered by IV counts as infusion therapy, and almost every state requires a physician to approve the standing orders and screening protocols behind it. Skip that step and the clinic is running an infusion service with no physician oversight on record. Add compounded peptides to the menu and that same medical director takes on a second layer of compliance.
The medical director writes and signs off on standing orders for every NAD+ infusion the clinic offers. They also approve peptide protocols, verify compounding pharmacy licensure, and set patient screening criteria. Charts get reviewed at set intervals to confirm the oversight is still active, not just filed away.
The FDA is still deciding which compounded peptides, including BPC-157 and TB-500, qualify for the approved 503A Bulks List. That decision has already changed direction more than once in 2026. Clinics need a medical director who tracks the current status and confirms a peptide is lawful before it ever reaches the treatment menu.
Most states require a nurse practitioner without full independent practice authority to work under a written collaborative or supervisory agreement with a physician. That agreement is what legally allows the NP to prescribe and to delegate IV infusion and compounded peptide services. Without it, the clinic has no valid physician oversight on record.
Medical Director Co. places physicians for NAD+ and peptide clinics at $799 per month, with no setup fees and no long-term contract required. That price covers a physician with direct experience in both IV infusion and compounding oversight, not a general medspa background. Placement typically takes 24 hours from the time you sign the agreement.
Closing the Compliance Gap Before It Costs You
NAD+ and peptide therapy clinics carry more regulatory weight than a standard medspa because they combine two service categories that regulators are actively watching in 2026. A medical director who only understands IV infusion, or only understands compounding, covers half the risk. Medical Director Co. places physicians who cover both in 24 hours, with an attorney-reviewed agreement built for this exact clinic type.
Your Next Patient Shouldn't Wait on Compliance
Match with one physician who covers IV infusion and peptide compounding, both, in a day.
Hire a Medical Director or
Collaborating Physician Today
